View Financial HealthSepterna 배당 및 자사주 매입배당 기준 점검 0/6Septerna 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.1%자사주 매입 수익률총 주주 수익률-0.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesSeeking Alpha • Jun 17Septerna: A De-Risking GPCR Story With Near-Term Upside CatalystsSummary Septerna combines a strong balance sheet with multiple near-term clinical catalysts, supporting its premium valuation. SEPN is funded into mid-2029, reducing near-term dilution risk and enabling continued investment in its GPCR-focused pipeline. Key upcoming catalysts include SEP-631 Phase 2 progression for chronic urticaria and SEP-479 Phase 1 data for hypoparathyroidism. Current valuation is demanding, with upside dependent on successful clinical execution and de-risking of lead assets. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • Jun 14Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$34.03, it would amount to US$287k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.4m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • May 27Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of May. If the sale is conducted around the recent share price of US$28.36, it would amount to US$335k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • May 21New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...Major Estimate Revision • May 20Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$65.7m to US$74.1m. Forecast losses expected to reduce from -US$1.94 to -US$1.81 per share. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$44.25 unchanged from last update. Share price rose 13% to US$28.01 over the past week.분석 기사 • May 14Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsAs you might know, Septerna, Inc. ( NASDAQ:SEPN ) just kicked off its latest quarterly results with some very strong...공시 • May 04Septerna, Inc., Annual General Meeting, Jun 26, 2026Septerna, Inc., Annual General Meeting, Jun 26, 2026.공시 • Apr 13Septerna, Inc. Announces Initiation of Phase 1 Trial for Oral PTH1R Agonist SEP-479 in HypoparathyroidismSepterna, Inc. announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its potent oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants. Dosing is underway in the SAD portion of the clinical trial, which will evaluate the safety and tolerability of SEP-479 at escalating oral doses. The MAD portion of the clinical trial is designed to evaluate the safety and tolerability of once-daily oral dosing of SEP-479 over multiple days of treatment, with secondary and exploratory endpoints including PK and PD, with the latter assessed by changes in endogenous PTH and serum calcium, as well as other biomarkers. Septerna anticipates reporting data from the trial in late 2026 or early 2027.공시 • Mar 11Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Mar 02Septerna, Inc. Announces Positive Phase 1 Data for Sep-631, an Oral Mrgprx2 Nam for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySepterna, Inc. announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modulator (NAM) of Mas-related G protein-coupled receptor X2 (MRGPRX2). These findings are consistent with the insurmountable NAM mechanism of SEP-631 observed preclinically and support potent target engagement and functional blockade of MRGPRX2 signaling in humans, providing clinical proof-of-mechanism. Phase 2 Development Strategy: Septerna plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of this year, following the completion of ongoing long-term toxicology studies. Following the CSU study initiation, the company also plans to pursue an open-label study in chronic inducible urticaria (CIndU), specifically in patients with symptomatic dermatographism. In a Phase 1 clinical trial, SEP-631 demonstrated favorable tolerability, once-daily pharmacokinetics and pharmacodynamic evidence of MRGPRX2 pathway inhibition.공시 • Jan 09Septerna, Inc. Appoints Mark A. Wilson as Chief Legal OfficerSepterna, Inc. has appointed Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company’s executive committee. During his tenure, Mr. Wilson served as lead attorney for several significant global development and commercialization collaborations, strategic corporate transactions and alternative financings, and he was responsible for the company’s global patent strategy. He joined Nektar in 2002 as Patent Counsel and held roles of increasing responsibility, including Vice President of Intellectual Property and General Counsel. Earlier in his career, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California.분석 기사 • Oct 05We're Not Worried About Septerna's (NASDAQ:SEPN) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Sep 30Septerna Appoints Keith Gottesdiener to its Board of Directors and as Chairperson of R&D Committee of the BoardSepterna, Inc. announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board. Dr. Gottesdiener has held leadership roles spanning academia, pharmaceutical R&D, and public biotechnology companies. He most recently served as President and Chief Executive Officer of Prime Medicine, Inc., leading the gene-editing company through IPO. Prior to that, Dr. Gottesdiener served as Chief Executive Officer of Rhythm Pharmaceuticals, Inc., where he oversaw the development and approval of setmelanotide for three indications in rare genetic forms of obesity. Before joining the biotechnology industry, Dr. Gottesdiener spent 16 years at Merck Research Laboratories, where he served as Worldwide Head of Late-Stage Development and Worldwide Head of Early Development, with major program responsibilities for the approval of more than 20 novel therapeutics and over 200 successful IND submissions. Earlier in his career, he was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Gottesdiener previously served on the board of directors of Intercept Pharmaceuticals, Inc. He received his M.D. from the University of Pennsylvania Medical School and his A.B. in Applied Mathematics from Harvard University.공시 • Jun 30+ 4 more updatesSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth IndexSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth Index공시 • Apr 30Septerna, Inc., Annual General Meeting, Jun 17, 2025Septerna, Inc., Annual General Meeting, Jun 17, 2025.분석 기사 • Apr 28Companies Like Septerna (NASDAQ:SEPN) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Feb 19Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R AgonistSepterna, Inc. announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial, both of which were without elevations in ALT, AST, and GGT liver enzyme levels. Dosing was discontinued for both study participants, and the bilirubin elevations were reversible. Importantly, there were no events of liver injury, cholestasis, or hemolysis across all participants, and there were no serious adverse events (SAEs) in the Phase 1 trial. In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation. In response to these Phase 1 events, Septerna has initiated non-clinical studies to investigate the underlying mechanism behind the observed effect.Seeking Alpha • Feb 04Septerna: Great In Theory, Needs ProofSummary Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule SEP-786 targets hypoparathyroidism, showing promising preclinical results and entering phase 1 trials, with data expected in mid-2025. SEPN has a $750mn market cap and $130mn in cash, providing a 6-7 quarter runway, but lacks clinical data until 2025. Despite the innovative platform, I recommend waiting for phase 1 data before investing due to the current lack of clinical proof. Read the full article on Seeking Alpha공시 • Jan 06Septerna, Inc Appoints Gil Labrucherie as Chief Financial OfficerSepterna, Inc. announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company’s finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar’s Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more than $1.5 billion in private and public equity capital and helped generate more than $1 billion in realized value from strategic partnering transactions. He currently serves on the board of Rezolute, Inc. Mr. Labrucherie holds a J.D. from the University of California Berkeley School of Law, a B.A. from the University of California Davis, and is a CFA charterholder and a member of the State Bar of California.공시 • Oct 26Septerna, Inc. has completed an IPO in the amount of $288 million.Septerna, Inc. has completed an IPO in the amount of $288 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 SEPN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: SEPN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Septerna 배당 수익률 vs 시장SEPN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (SEPN)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.1%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (SEPN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 SEPN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 SEPN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 SEPN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: SEPN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/26 18:18종가2026/06/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Septerna, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Joshua SchimmerCantor Fitzgerald & Co.Seamus FernandezGuggenheim Securities, LLCRaghuram SelvarajuH.C. Wainwright & Co.7명의 분석가 더 보기
Seeking Alpha • Jun 17Septerna: A De-Risking GPCR Story With Near-Term Upside CatalystsSummary Septerna combines a strong balance sheet with multiple near-term clinical catalysts, supporting its premium valuation. SEPN is funded into mid-2029, reducing near-term dilution risk and enabling continued investment in its GPCR-focused pipeline. Key upcoming catalysts include SEP-631 Phase 2 progression for chronic urticaria and SEP-479 Phase 1 data for hypoparathyroidism. Current valuation is demanding, with upside dependent on successful clinical execution and de-risking of lead assets. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • Jun 14Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 8k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of June. If the sale is conducted around the recent share price of US$34.03, it would amount to US$287k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.4m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • May 27Chief People Officer notifies of intention to sell stockSamira Shaikhly intends to sell 12k shares in the next 90 days after lodging an Intent To Sell Form on the 26th of May. If the sale is conducted around the recent share price of US$28.36, it would amount to US$335k. Since March 2026, Samira has owned 793.00 shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • May 21New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)Septerna, Inc. ( NASDAQ:SEPN ) shareholders will have a reason to smile today, with the analysts making substantial...
Major Estimate Revision • May 20Consensus revenue estimates increase by 13%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$65.7m to US$74.1m. Forecast losses expected to reduce from -US$1.94 to -US$1.81 per share. Pharmaceuticals industry in the US expected to see average net income decline 13% next year. Consensus price target of US$44.25 unchanged from last update. Share price rose 13% to US$28.01 over the past week.
분석 기사 • May 14Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsAs you might know, Septerna, Inc. ( NASDAQ:SEPN ) just kicked off its latest quarterly results with some very strong...
공시 • May 04Septerna, Inc., Annual General Meeting, Jun 26, 2026Septerna, Inc., Annual General Meeting, Jun 26, 2026.
공시 • Apr 13Septerna, Inc. Announces Initiation of Phase 1 Trial for Oral PTH1R Agonist SEP-479 in HypoparathyroidismSepterna, Inc. announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its potent oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants. Dosing is underway in the SAD portion of the clinical trial, which will evaluate the safety and tolerability of SEP-479 at escalating oral doses. The MAD portion of the clinical trial is designed to evaluate the safety and tolerability of once-daily oral dosing of SEP-479 over multiple days of treatment, with secondary and exploratory endpoints including PK and PD, with the latter assessed by changes in endogenous PTH and serum calcium, as well as other biomarkers. Septerna anticipates reporting data from the trial in late 2026 or early 2027.
공시 • Mar 11Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.Septerna, Inc. has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Mar 02Septerna, Inc. Announces Positive Phase 1 Data for Sep-631, an Oral Mrgprx2 Nam for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySepterna, Inc. announced positive results from its Phase 1 clinical trial evaluating SEP-631, a potent and selective oral negative allosteric modulator (NAM) of Mas-related G protein-coupled receptor X2 (MRGPRX2). These findings are consistent with the insurmountable NAM mechanism of SEP-631 observed preclinically and support potent target engagement and functional blockade of MRGPRX2 signaling in humans, providing clinical proof-of-mechanism. Phase 2 Development Strategy: Septerna plans to initiate a Phase 2b clinical trial of SEP-631 in chronic spontaneous urticaria (CSU) in the second half of this year, following the completion of ongoing long-term toxicology studies. Following the CSU study initiation, the company also plans to pursue an open-label study in chronic inducible urticaria (CIndU), specifically in patients with symptomatic dermatographism. In a Phase 1 clinical trial, SEP-631 demonstrated favorable tolerability, once-daily pharmacokinetics and pharmacodynamic evidence of MRGPRX2 pathway inhibition.
공시 • Jan 09Septerna, Inc. Appoints Mark A. Wilson as Chief Legal OfficerSepterna, Inc. has appointed Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company’s executive committee. During his tenure, Mr. Wilson served as lead attorney for several significant global development and commercialization collaborations, strategic corporate transactions and alternative financings, and he was responsible for the company’s global patent strategy. He joined Nektar in 2002 as Patent Counsel and held roles of increasing responsibility, including Vice President of Intellectual Property and General Counsel. Earlier in his career, Mr. Wilson was an associate at Reed & Associates, a patent law firm in Menlo Park, California, where he represented both start-up and Fortune 500 companies. Mr. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California.
분석 기사 • Oct 05We're Not Worried About Septerna's (NASDAQ:SEPN) Cash BurnWe can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Sep 30Septerna Appoints Keith Gottesdiener to its Board of Directors and as Chairperson of R&D Committee of the BoardSepterna, Inc. announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board. Dr. Gottesdiener has held leadership roles spanning academia, pharmaceutical R&D, and public biotechnology companies. He most recently served as President and Chief Executive Officer of Prime Medicine, Inc., leading the gene-editing company through IPO. Prior to that, Dr. Gottesdiener served as Chief Executive Officer of Rhythm Pharmaceuticals, Inc., where he oversaw the development and approval of setmelanotide for three indications in rare genetic forms of obesity. Before joining the biotechnology industry, Dr. Gottesdiener spent 16 years at Merck Research Laboratories, where he served as Worldwide Head of Late-Stage Development and Worldwide Head of Early Development, with major program responsibilities for the approval of more than 20 novel therapeutics and over 200 successful IND submissions. Earlier in his career, he was Associate Professor of Medicine at Columbia University College of Physicians and Surgeons. Dr. Gottesdiener previously served on the board of directors of Intercept Pharmaceuticals, Inc. He received his M.D. from the University of Pennsylvania Medical School and his A.B. in Applied Mathematics from Harvard University.
공시 • Jun 30+ 4 more updatesSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth IndexSepterna, Inc.(NasdaqGM:SEPN) dropped from Russell 3000E Growth Index
공시 • Apr 30Septerna, Inc., Annual General Meeting, Jun 17, 2025Septerna, Inc., Annual General Meeting, Jun 17, 2025.
분석 기사 • Apr 28Companies Like Septerna (NASDAQ:SEPN) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Feb 19Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R AgonistSepterna, Inc. announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of two unanticipated severe (Grade 3) events of elevated unconjugated bilirubin in the MAD portion of the Phase 1 trial, both of which were without elevations in ALT, AST, and GGT liver enzyme levels. Dosing was discontinued for both study participants, and the bilirubin elevations were reversible. Importantly, there were no events of liver injury, cholestasis, or hemolysis across all participants, and there were no serious adverse events (SAEs) in the Phase 1 trial. In completed 28-day preclinical toxicology studies, SEP-786 was generally well-tolerated, without predicted risk of bilirubin elevation. In response to these Phase 1 events, Septerna has initiated non-clinical studies to investigate the underlying mechanism behind the observed effect.
Seeking Alpha • Feb 04Septerna: Great In Theory, Needs ProofSummary Septerna's Native Complex platform isolates GPCRs in their native form, enabling advanced drug discovery for previously undruggable targets, including oral small-molecule therapeutics. Lead molecule SEP-786 targets hypoparathyroidism, showing promising preclinical results and entering phase 1 trials, with data expected in mid-2025. SEPN has a $750mn market cap and $130mn in cash, providing a 6-7 quarter runway, but lacks clinical data until 2025. Despite the innovative platform, I recommend waiting for phase 1 data before investing due to the current lack of clinical proof. Read the full article on Seeking Alpha
공시 • Jan 06Septerna, Inc Appoints Gil Labrucherie as Chief Financial OfficerSepterna, Inc. announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company’s finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar’s Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more than $1.5 billion in private and public equity capital and helped generate more than $1 billion in realized value from strategic partnering transactions. He currently serves on the board of Rezolute, Inc. Mr. Labrucherie holds a J.D. from the University of California Berkeley School of Law, a B.A. from the University of California Davis, and is a CFA charterholder and a member of the State Bar of California.
공시 • Oct 26Septerna, Inc. has completed an IPO in the amount of $288 million.Septerna, Inc. has completed an IPO in the amount of $288 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering